19-hydroxyandrostenedione as a new hypertensinogenic agent.
The hypertensiogenic effects of 19-hydroxyandrostenedione (19-OH-A-dione) reported previously to be an amplifier of the action of aldosterone were evaluated using the same experimental procedures as for DOCA-salt hypertension in rats. The 19-OH-A-dione treated rats developed high blood pressure, hypokalemia, suppressed plasma renin activity and low plasma aldosterone and corticosterone concentrations as the DOCA treated rats did. The results demonstrate that 19-OH-A-dione amplifies the action of endogenous aldosterone and causes a hypertensive state simulating mineralocorticoid excess. Amplifiers of the action of aldosterone are considered to work as hypertensinogenic agents in the presence of the adrenal cortex.
D000450:Aldosterone / Q000097:blood; D000735:Androstenedione / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D003345:Corticosterone / Q000097:blood; D003900:Desoxycorticosterone / Q000494:pharmacology; D006973:Hypertension / Q000139:chemically induced*; D008297:Male; D011188:Potassium / Q000097:blood; D051381:Rats; D012083:Renin / Q000097:blood
D000735:Androstenedione; D003900:Desoxycorticosterone; D000450:Aldosterone; C003582:11-hydroxyandrostenedione; C011482:19-hydroxy-4-androstene-3,17-dione; D012083:Renin; D011188:Potassium; D003345:Corticosterone